Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,106 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tablets Intervention Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Culturally-adapted Colorectal Cancer Screening Decision Aid Designed for American Indians

NCT03569761
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Colorectal Cancer Screening Decision Aid, Control Group
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
50 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lumberton, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Telehealth Group Intervention for Perinatal Depressive Symptoms

NCT03932760
View directory record Official record
Conditions
Perinatal Depression
Interventions
UPLIFT Program, Attention Control Group
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Not applicable Interventional Results available

Pregabalin for the Treatment of Pain After Posterior Spinal Fusions

NCT01366196
View directory record Official record
Conditions
Lumbar Spinal Fusions
Interventions
Pregabalin 150 mg, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
21 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 21, 2026, 6:52 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Interactive Physical and Cognitive Exercise System (v3) for Mild Cognitive Impairment (MCI)

NCT05009524
View directory record Official record
Conditions
MCI, Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
iPACES (interactive Physical and Cognitive Exercise System), PACE (Physical and Cognitive Exercise)
Device
Lead sponsor
iPACES LLC
Industry
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Clifton Park, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 21, 2026, 6:52 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

NCT04557059
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radiotherapy, LHRHa, Apalutamide
Radiation · Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years and older · Male only
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

NCT02722967
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions
Aripiprazole + IEM (Ingestible Event Marker)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 21, 2026, 6:52 AM EDT
Withdrawn Not applicable Interventional

Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting

NCT02936271
View directory record Official record
Conditions
Venous Insufficiency of Leg, Venous Reflux, Varicose Veins, Lower Extremity Edema Chronic
Interventions
Vasculera, Placebo
Other
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 2Phase 3 Interventional Results available

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

NCT01903265
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
TNX-102 SL 2.8mg, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Sacramento, California • Denver, Colorado • Brooksville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 1 Interventional

Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma

NCT03458546
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
Roflumilast
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment

NCT01319279
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Hydrocodone bitartrate extended-release tablet
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 21, 2026, 6:52 AM EDT
Not yet recruiting Phase 2 Interventional

SAMe in Prevention of Oxaliplatin-associated Liver Injury

NCT06258525
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury, Sinusoidal Obstruction Syndrome, 5-Fluorouracil Toxicity, Liver Toxicity, Chemically-Induced
Interventions
Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery
Radiation · Dietary Supplement · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 2 Interventional

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06049017
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Anaheim, California • Newport Beach, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 4 Interventional

Tranexamic Acid in Revision Total Joint Arthroplasty

NCT02877381
View directory record Official record
Conditions
Revision Total Knee Arthroplasty, Revision Total Hip Arthroplasty, Acute Blood Loss Anemia
Interventions
Revision Total Knee Arthroplasty (TKA), Revision Total Hip Arthroplasty (THA)
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

NCT03251144
View directory record Official record
Conditions
HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
Interventions
Switch to E/C/FTC/TAF daily
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

NCT03522506
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 21, 2026, 6:52 AM EDT
Recruiting Not applicable Interventional

Visuomotor Prosthetic for Paralysis

NCT01958086
View directory record Official record
Conditions
Quadriplegia
Interventions
Neural Communication System
Device
Lead sponsor
Richard A. Andersen, PhD
Other
Eligibility
22 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2031
U.S. locations
3
States / cities
Los Angeles, California • Pasadena, California • Pomona, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

NCT00803686
View directory record Official record
Conditions
Phase 1 Pharmacodynamic Study
Interventions
Oral rsCT tablet, Oral Placebo Tablet, Fortical (rsCT) nasal spray
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Therapy for RefrACTORy Migraine Study

NCT02518464
View directory record Official record
Conditions
Migraine, Headache, Migraine Headache
Interventions
Ticagrelor 90 mg twice per day
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interactive Digital Intervention to Prevent Violence Among Young Adults

NCT03820609
View directory record Official record
Conditions
Sexual Assault
Interventions
Digital Intervention
Behavioral
Lead sponsor
Happy People Games, LLC
Other
Eligibility
18 Years to 24 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Warwick, Rhode Island • Clemson, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

NCT03672487
View directory record Official record
Conditions
Chagas Disease
Interventions
Benznidazole, Placebo Oral Tablet
Drug
Lead sponsor
Tulane University School of Public Health and Tropical Medicine
Other
Eligibility
13 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
San Diego, California • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 6:52 AM EDT
Terminated Early Phase 1 Interventional Results available

Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial

NCT04825275
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult
Interventions
Posaconazole Pill
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 21, 2026, 6:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessing Pyridium for Post-Sling Urinary Retention

NCT03302936
View directory record Official record
Conditions
Urinary Retention
Interventions
Phenazopyridine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 21, 2026, 6:52 AM EDT